Definitive experimental evidence from mouse cancer models and strong correlative clinical
data gave rise to the Cancer Immunoediting concept that explains the dual host-protective …

The technological advances occurred in the last few years have led to a great increase in
the number of tumor associated antigens (TAA) that are currently available for clinical …

Abbreviations used ALL acute lymphoblastic leukemia á AML acute myeloid leukemia á APL
acute promyelocytic leukemia á CML chronic myelogenous leuke mia á CTL cytotoxic T …

The Wilms tumor (WT1) gene has been reported to be preferentially expressed in acute
leukemia cells, regardless of leukemia subtype and chronic myelogenous leukemia cells in …

Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …

A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …

Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …

It has long been a matter of debate whether tumors are spontaneously immunogenic in
patients. With the availability of sensitive methods, naturally occurring T cells directed …

Antigens implicated in the graft-versus-leukemia (GVL) effect in chronic myeloid leukemia
(CML) include WT1, PR1, and BCR-ABL. To detect very low frequencies of these antigen …

To date an increasing number of T-cell epitopes derived from various tumor-associated
antigens have been reported, and they proved to play significant roles for tumor rejection …